New pill shows promise against Hard-to-Treat cancers

NCT ID NCT05585320

Ongoing Disease control Sponsor: Immuneering Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aims to find the safest dose and see if the drug can shrink tumors. About 209 adults are participating across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMM-1-104 (an oral MEK1/2 inhibitor), given alone or with gemcitabine and nab-paclitaxel
What this could lead to: If successful, this could provide a new oral treatment option for people with certain advanced cancers that have RAS mutations, potentially shrinking tumors or slowing their growth.
What could go wrong: This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects from the drug or chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma cutaneous melanoma melanoma Melanoma, Cutaneous Malignant metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR MALIGNANT MELANOMA (CUTANEOUS) NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Cancer Institute

Durham, North Carolina, 27710, United States
Florida Cancer Specialists and Research Institute

Lake Mary, Florida, 32746, United States
Hematology Oncology Associates of Central New York

East Syracuse, New York, 13057, United States
Levine Cancer Center

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Scottsdale, Arizona, 85259, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
Northwestern University

Chicago, Illinois, 60611, United States
SCRI Oncology Partners

Nashville, Tennessee, 27203, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
University of California San Diego

San Diego, California, 92037, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Wisconsin Clinical Science Center

Madison, Wisconsin, 53792, United States
Weill Cornell Medicine

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.